ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31
ANI PHARMACEUTICALS INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)
Close on Oct 19, 2026
- Market cap
- $1.59B
- P/E (TTM)
- 15.4
- Dividend yield
- –
ANI PHARMACEUTICALS INC revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands | $483.93M | $294.34M | $197.50M | $81.15M | – | – | – | – | – | – | 54.8% | +64.4% |
| Generics and Other | $399.43M | $320.03M | $289.31M | $235.24M | – | – | – | – | – | – | 45.2% | +24.8% |
| Canada [Member] | – | – | – | – | – | – | $6.88M | $4.69M | $0 | $0 | – | – |
| United States [Member] | – | – | – | – | – | – | $199.66M | $196.89M | $176.84M | $128.62M | – | – |
| Generics, Established Brands, and Other | – | – | $374.70M | $274.70M | $216.14M | $208.48M | – | – | – | – | – | – |
| Rare Disease | – | – | $112.12M | $41.69M | $0 | – | – | – | – | – | – | – |
| Operating income | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Generics and Other | $154.99M | $116.02M | $105.93M | $85.48M | – | – | – | – | – | – | +33.6% |
| Rare Disease and Brands | $141.24M | $72.47M | $89.17M | $10.54M | – | – | – | – | – | – | +94.9% |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rare Disease and Brands total net revenues | $483.95M | $294.34M | $197.50M | $81.15M | – | – | – | – | – | – | 54.8% | +64.4% |
| Rare Disease total net revenues | $422.65M | $229.60M | $112.12M | $41.69M | – | – | – | – | – | – | 47.8% | +84.1% |
| Generics and Other total net revenues | $399.41M | $320.03M | $289.32M | $235.24M | – | – | – | – | – | – | 45.2% | +24.8% |
| Generic pharmaceutical products | $384.11M | $301.00M | $269.45M | $210.12M | $143.57M | $147.26M | $128.73M | $117.45M | $118.44M | $95.20M | 43.5% | +27.6% |
| Cortrophin Gel | $347.78M | $198.09M | $112.12M | $41.69M | – | – | – | – | – | – | 39.4% | +75.6% |
| ILUVIEN and YUTIQ | $74.87M | $31.51M | $0 | $0 | – | – | – | – | – | – | 8.5% | +137.6% |
| Brands | $61.31M | $64.74M | $85.38M | $39.46M | – | – | – | – | – | – | 6.9% | -5.3% |
| Unapproved Products | $24.10M | $22.40M | $22.40M | $14.20M | $16.20M | $16.90M | $20.70M | $24.90M | $27.60M | $34.30M | 2.7% | +7.6% |
| Royalties and other pharmaceutical services | $15.30M | $19.03M | $19.87M | $25.12M | – | – | – | – | – | – | 1.7% | -19.6% |
| Sales of established brand pharmaceutical products, royalties, and other pharmaceutical services | – | – | $105.25M | $64.58M | $72.57M | $47.96M | $63.77M | $60.55M | $50.92M | $26.44M | – | – |
| Sales of contract manufactured products | – | – | – | $16.11M | $10.04M | $9.22M | $11.14M | $9.12M | $7.05M | $5.54M | – | – |
| Other | – | – | – | $693.00K | $1.86M | $783.00K | $980.00K | $929.00K | $440.00K | $1.44M | – | – |
| Royalties from licensing agreements | – | – | – | $5.37M | $11.80M | $1.40M | $807.00K | $12.50M | $0 | $0 | – | – |
| Product development services | – | – | – | $2.95M | $1.31M | $1.86M | $1.13M | $1.02M | $0 | $0 | – | – |
| Performance Obligation From Prior Period [Member] | – | – | – | – | – | – | $10.20M | $5.30M | – | – | – | – |
| Sales of rare disease pharmaceutical products | – | – | $112.12M | $41.69M | $0 | – | – | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $852.44M | $604.99M | $486.25M | $312.43M | $211.89M | $202.88M | $199.66M | $196.89M | – | – | 96.5% | +40.9% |
| International | $30.92M | $9.39M | $565.00K | $3.96M | – | – | – | – | – | – | 3.5% | +229.4% |
| Canada | – | – | $565.00K | $3.96M | $4.24M | $5.59M | $6.88M | $4.69M | – | – | – | – |
From the segment and revenue-disaggregation notes of Ani Pharmaceuticals's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.